Harnessing zika virus: A potential game-changer in cancer immunotherapy.

Sarah Julie*

Department of Microbiology & Immunology, Wright State University, United States

Introduction

The quest for innovative cancer therapies has led to the exploration of oncolytic viruses, a promising approach that harnesses the power of viruses to selectively target and destroy cancer cells. One of the most intriguing candidates in this field is the Zika virus, initially notorious for its association with birth defects. Recent research suggests that a modified, oncolytic Zika virus might hold the key to promoting intratumoral T cell infiltration, a critical factor in the fight against cancer. In this article, we delve into the potential of oncolytic Zika virus as a novel immunotherapy for cancer. Oncolytic viruses are viruses that preferentially infect and replicate within cancer cells, leading to their destruction. This unique approach not only kills cancer cells directly but also triggers an immune response against the tumor, enhancing the body's ability to recognize and eliminate cancer cells throughout the body.

Several oncolytic viruses, including the herpes simplex virus, adenoviruses, and the measles virus, have shown promise in clinical trials. However, the Zika virus, with its potential to promote intratumoral T cell infiltration, presents an exciting and relatively unexplored avenue for cancer therapy. Zika virus gained global attention due to its outbreak in 2015-2016, primarily in Latin America, and its association with microcephaly and other birth defects in newborns. However, recent studies have revealed a potential silver lining in this ominous cloud. Scientists have discovered that a modified, oncolytic Zika virus could target glioblastoma, an aggressive form of brain cancer, while sparing healthy brain tissue.

One of the critical components of a successful cancer immunotherapy is the infiltration of T cells into the tumor microenvironment. T cells are specialized immune cells responsible for recognizing and destroying cancer cells. However, tumors often develop mechanisms to evade T cell detection, creating an immunosuppressive environment. The oncolytic Zika virus appears to address this challenge by promoting intratumoral T cell infiltration. In preclinical studies, the virus selectively targets cancer cells, causing them to release danger signals that attract T cells to the tumor site. This influx of T cells creates an immune response within the tumor microenvironment, effectively turning "cold" tumors (with low immune cell infiltration) into "hot" tumors (with high immune cell infiltration).

The potential of the oncolytic Zika virus to boost intratumoral T cell infiltration has significant implications for cancer immunotherapy. Combination therapies that pair oncolytic viruses with immune checkpoint inhibitors, such as PD-1 or CTLA-4 inhibitors, can enhance the immune response and improve treatment outcomes. By first priming the tumor with the oncolytic Zika virus to promote T cell infiltration, followed by the administration of checkpoint inhibitors, researchers aim to unleash the full power of the immune system against cancer cells. This two-pronged approach offers a potent strategy to overcome immunosuppressive tumor environments and improve the response to immunotherapy.

As research in oncolytic virotherapy continues to advance, the collaboration between virologists, immunologists, and oncologists holds the promise of novel, effective, and safer therapies for cancer patients. The oncolytic Zika virus may have started as a global health concern but could ultimately become a game-changer in the fight against one of humanity's most formidable adversaries: cancer [5].

Conclusion

The concept of using the Zika virus, once feared for its association with birth defects, as a therapeutic tool against cancer is a remarkable example of scientific innovation. By exploiting the virus's ability to promote intratumoral T cell infiltration, researchers are unlocking new possibilities in cancer immunotherapy. The oncolytic Zika virus, when used in combination with immune checkpoint inhibitors and other emerging immunotherapies, has the potential to transform the treatment landscape for a wide range of cancers. This approach offers hope for patients with previously untreatable tumors and highlights the dynamic nature of cancer research.

References

1. Paz-Bailey G, Rosenberg ES, Doyle K, et al. Persistence of Zika virus in body fluids. N Engl J Med. 2018;379(13):1234-43.
2. Nduom EK, Wei J, Yaghi NK, et al. PD-L1 expression and prognostic impact in glioblastoma. Neuro-oncology. 2015;18(2):195-205.
3. Schoenfeld AJ, Hellmann MD. Acquired resistance to immune checkpoint inhibitors. Cancer cell. 2020;37(4):443-55.

***Correspondence to:** Sarah Julie, Department of Microbiology & Immunology, Wright State University, United States, E-mail: julies@wright.edu

***Received:** 02-Jan-2024, Manuscript No. AAICR-23-115708; **Editor assigned:** 03-Jan-2024, Pre QC No. AAICR-23-115708(PQ); **Reviewed:** 17-Jan-2024, QC No. AAICR-23-115708; **Revised:** 25-Jan-2024, Manuscript No. AAICR-23-115708(R); **Published:** 27-Jan-2024, DOI: 10.35841/aaicr-7.1.175*

***Citation:** Julie S. Harnessing zika virus: A potential game-changer in cancer immunotherapy. Immunol Case Rep. 2024;7(1):175*

4. Zhu Z, Mesci P, Bernatchez JA, et al. Zika virus targets glioblastoma stem cells through a SOX2-integrin αvβ5 axis. Cell stem cell. 2020;26(2):187-204.
5. Spranger S, Dai D, Horton B, et al. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer cell. 2017;31(5):711-23.

Citation: *Julie S. Harnessing zika virus: A potential game-changer in cancer immunotherapy. Immunol Case Rep. 2024;7(1):175*